Wells Fargo analyst Yanan Zhu assigned a Hold rating to Sangamo Biosciences (SGMO – Research Report) yesterday and set a price target of ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), with ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

(SGMO) on Tuesday reported third-quarter earnings of $10.7 million. On a per-share basis, the Richmond, California-based company said it had profit of 4 cents. The results exceeded Wall Street ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

On Friday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $2.87 which represents a slight increase of $0.06 or 2.14% from the prior close of $2.81. The stock opened at $2 ...